3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
4
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Gynecologic
4
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
11
Stomach Neoplasms
6
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Salivary Gland Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Interventions
Bevacizumab
39
Paclitaxel
35
pembrolizumab
27
Carboplatin
27
Specimen Handling
21
olaparib
19
Magnetic Resonance Spectroscopy
19
Gemcitabine
19
liposomal doxorubicin
17
Cyclophosphamide
16
niraparib
13
fludarabine
12
Topotecan
12
Cisplatin
12
Biopsy
12
Taxes
9
Nivolumab
8
Immunoglobulin G
8
Fulvestrant
8
Doxorubicin
8
Disulfides
8
Surveys and Questionnaires
7
palbociclib
6
aldesleukin
6
Oxaliplatin
6
Letrozole
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
trastuzumab deruxtecan
×
90 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled
NCT07340164
2026-04-20
TROY
Yonsei University
Phase 2
Recruiting
116 enrolled